ReviewCells2026
Oncolytic Viruses in Cancer Immunotherapy: From Molecular Engineering to Clinical Translation.
Review in Cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Emerging and Re-Emerging Viral Pathogens in Oncolytic Virotherapy: A Comprehensive Review.Reviews in medical virology · 2026Review
- Recent advances in oncolytic virotherapy: insights from clinical trials and combination treatment strategies.Virology journal · 2026Review
- The emerging role of oncolytic virotherapy in genitourinary malignancies.Frontiers in cell and developmental biology · 2026Review
- Advances and Future Expectations in Oncolytic Virus Therapy for Glioblastoma: A Systematic Review of Clinical Trials.Clinical Medicine Insights. Oncology · 2026Review
- The interplay between oncolytic viruses, Toll-like receptor signaling, and chemotherapy in overcoming tumor immune tolerance.Frontiers in cellular and infection microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer immunotherapy has transformed modern oncology, yet durable responses remain limited for many patients due to immune exclusion, adaptive resistance, and tumor heterogeneity. Oncolytic viruses (OVs) have emerged as a novel class of immunotherapeutics that unify direct tumor cytolysis with stimulation of antitumor immunity. By inducing immunogenic cell death (ICD) and releasing tumor-associated antigens (TAAs), OVs remodel the tumor microenvironment (TME) into an inflamed and immune-permissive niche capable of enabling systemic immune activation. Rapid advances in viral engineering have strengthened the translational potential of OVs through tumor-selective gene deletions, tumor-specific promoters, microRNA-based detargeting, and receptor-retargeting strategies that collectively enhance safety, specificity, and intratumoral propagation. Next-generation OVs are increasingly "armed" with immunostimulatory payloads-including cytokines, chemokines, checkpoint inhibitors, bispecific T-cell engagers, and suicide gene systems-allowing localized immune modulation with reduced systemic toxicity. These innovations have propelled significant clinical progress, exemplified by the approvals of talimogene laherparepvec (T-VEC), G47Δ, and H101, and have driven a surge of combination trials integrating OVs with immune checkpoint blockade, adoptive cell therapies, radiotherapy, and targeted therapies to overcome multilayered tumor immune resistance. Despite this momentum, clinical implementation remains challenged by antiviral immunity, heterogeneous viral distribution, stromal barriers, and dynamic interferon (IFN) signaling in the TME. Emerging delivery approaches, including carrier cell systems, nanotechnology-enabled viral shielding, and synthetic virology platforms, offer promising solutions to these limitations. Oncolytic virotherapy is rapidly evolving into a multifunctional immunotherapeutic platform capable of reshaping antitumor responses at both local and systemic levels. By integrating advanced viral engineering with rational combination strategies and innovative delivery technologies, OVs hold substantial potential to overcome current barriers in cancer immunotherapy and advance precision oncology. Continued translational research will be essential to fully harness their therapeutic impact and broaden their clinical applicability.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.